Stocks · News reference
Lifeward (NASDAQ:LFWD) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.34) by 8.96 percent. This is a 61.07 percent increase over losses of $(3.75) per share from the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Publication of an independent, investigator-initiated peer-reviewed study which provides long-term real-world evidence on the safety, utilization and user experience of the ReWalk® Personal Exoskeleton in individuals
Filed: 2026-10-08 AccNo: 0001178913-26-004746 Size: 190 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
An independent peer-reviewed study published in the Internet Journal of Allied Health Sciences and Practice demonstrates that individuals with chronic spinal cord injury using Lifeward's ReWalk personal exoskeleton showed significant improvements in daily activity performance, satisfaction, and reduced pain compared to wheelchair use. All 12 study participants successfully performed kitchen tasks while standing, 10 performed grooming tasks, and 8 reported improvements in bowel and bladder function. The findings support ReWalk's clinical value as Lifeward expands commercial distribution and reports 13% year-over-year sales growth to $2.5 million in Q2 2026.